Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
- Details
- Category: Boehringer Ingelheim
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (NSCLC) could benefit from targeted therapy based on their lung cancer type, over the use of chemotherapy.(1) Test results to identify EGFR mutations were not available prior to deciding on therapy for nearly one in five (18%*) patients for whom a test was ordered.
Abbott seeks to terminate Alere acquisition
- Details
- Category: Abbott
Abbott (NYSE: ABT) has filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value following the merger agreement. In the 10 months following the Jan. 30, 2016, signing of the agreement, Alere has suffered a series of damaging business developments, including the government eliminating the billing privileges of a substantial Alere division,
NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors
- Details
- Category: Novo Nordisk
Novo Nordisk has announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with haemophilia A or B with inhibitors.(1) Efficacy also remained high for bleeds treated after 4 hours.
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
- Details
- Category: Novartis
Novartis today announced results from the first-ever international survey of patients with myeloproliferative neoplasms (MPNs), specifically myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET), which indicate that the majority of patients living with these MPNs experience a reduced quality of life.
IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery
- Details
- Category: Pfizer
IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) have announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer.
Takeda to invest more than 100 million Euros in dengue vaccine manufacturing plant in Germany
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (TOKYO:4502) ("Takeda") has announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. This represents a major step by Takeda toward meeting important unmet needs in dengue prevention. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease.
Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and China Southeast University Institute of Life Sciences have announced the start of a joint research project to develop new treatment approaches for hearing loss through regeneration of hair cells from inner ear stem cells. The new collaboration combines the expertise of Professor Renjie Chai, one of the worldwide leaders in the field of hearing loss,
More Pharma News ...
- AstraZeneca takes latest scientific advances in oncology to major US and European congresses
- GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles
- Lilly announces top-line results of solanezumab phase 3 clinical trial
- Shire to establish rare disease innovation hub in Cambridge, Mass.
- Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
- Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
- Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study